
Masimo (MASI) Stock Forecast & Price Target
Masimo (MASI) Analyst Ratings
Bulls say
Masimo Corp's positive outlook is supported by a robust growth trajectory within its core pulse oximetry business as well as significant advancements in advanced monitoring technologies, including capnography and hemodynamics, driving increased revenue. The company is expected to achieve consistent earnings before interest and taxes (EBIT) margin expansion, projected at approximately 70 and 60 basis points year-over-year growth for fiscal years 2026 and 2027, indicating improving profitability. With anticipated revenue growth rates exceeding 10% in both the international pulse oximetry market and from new product launches in advanced monitoring platforms, Masimo's long-term financial prospects appear strong.
Bears say
Masimo Corporation faces significant financial headwinds, including projected tariff impacts of approximately $16 million to $17 million for FY25, which could adversely affect operating margins by around 110 basis points. The company’s cautious revenue forecasts are compounded by various risks, such as increased competition, pressures on hospital demand for capital equipment, and potential delays related to regulatory approvals and product launches. Furthermore, vulnerabilities in sales force retention and integration of mergers and acquisitions add layers of uncertainty, suggesting challenges in achieving sustainable revenue growth and profitability in the healthcare sector.
This aggregate rating is based on analysts' research of Masimo and is not a guaranteed prediction by Public.com or investment advice.
Masimo (MASI) Analyst Forecast & Price Prediction
Start investing in Masimo (MASI)
Order type
Buy in
Order amount
Est. shares
0 shares